Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 7, 2016, Pages 1148-1158

  Menter, A ^a   Papp, K A ^b   Gooderham, M ^c   Pariser, D M ^d   Augustin, M ^e   Kerdel, F A ^f   Fakharzadeh, S ^g   Goyal, K ^g   Calabro, S ^g   Langholff, W ^h   Chavers, S ⁱ   Naessens, D ^j   Sermon, J ^j   Krueger, G G ^k  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b K Papp Clinical Research and Probity Medical Research   (Canada)

^c Skin Centre for Dermatology   (Canada)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f Florida Academic Dermatology Centers   (United States)

^g Janssen Scientific Affairs LLC   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^j Janssen Cilag EMEA Belgium   (Belgium)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ADULT; ARTICLE; BIOLOGICAL THERAPY; BODY MASS; DRUG EFFICACY; DRUG TREATMENT FAILURE; EUROPEAN; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORTH AMERICAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOLOGY; SOUTH AND CENTRAL AMERICA; SURVIVAL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84976462897     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13611     Document Type: Article

References (30)

1. Yeung H, Wan J, van Voorhees AS et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013; 68: 64–72.
2. Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol 2014; 170: 261–273.
3. Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs. conventional systemic therapies. J Drugs Dermatol 2014; 13: 848–853.
4. Umezawa Y, Nobeyama Y, Hayashi M et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol 2013; 40: 1008–1013.
5. van den Reek JMPA, Zweegers J, Kievit W et al. ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol 2014; 71: 1189–1196.
6. Menting SP, Sitaram AS, Bonnerjee-van der Stok HM et al. Drug survival not significantly different between biologics in patients with psoriasis vulgaris: a single center database analysis. Br J Dermatol 2014; 171: 875–883.
7. Bonafede M, Johnson BH, Fox KM et al. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatol Treat 2013; 24: 369–373.
8. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091–1096.
9. Esposito M, Gisondi P, Cassano N et al. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 2013; 169: 666–672.
10. Cao Z, Carter C, Wilson KL, Schenkel B. Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis. J Dermatol Treat 2015; 26: 113–120.
11. Herrera-Acosta E, Suarez-Perez JA, Aguilera J et al. Survival rate of etanercept for psoriasis in real life: a multicentre observational study. Eur J Dermatol 2014; 24: 619–620.
12. Gniadecki R, Bang B, Bryld LE et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 2015; 172: 244–252.
13. Levin EC, Gupta R, Brown G et al. Biologic fatigue in psoriasis. J Dermatolog Treat 2014; 25: 78–82.
14. Strober BE, Bissonnette R, Fiorentino D et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real world setting: results from a large, prospective, observational study (PSOLAR). J Am Acad Dermatol. doi: 10.1016/j.jaad.2015.12.017.
15. Papp KA, Strober B, Augustin M et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012; 11: 1210–1217.
16. Kimball AB, Leonardi C, Stahle M et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicenter, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014; 171: 137–147.
17. Warren RB, Smith CH, Yiu ZZ et al. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; 135: 2632–2640.
18. ®. (ustekinumab) [Package Insert]. Janssen Biotech, Inc, Horsham, PA, 2013.
19. ®. (infliximab) [Package Insert]. Janssen Biotech, Inc, Horsham, PA, 2013.
20. Humira. (adalimumab) [Package Insert]. AbbVie Inc, North Chicago, IL, 2013.
21. Enbrel. (etanercept) [Package Insert]. Immunex Corporation, Thousand Oaks, CA, 2013.
22. Clemmenson A, Spon M, Skov L et al. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25: 1037–1040.
23. López-Ferrer A, Vilarrasa E, Gich IJ, Puig L. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol 2013; 169: 1141–1147.
24. Ruis Salas V, Puig L, Alomar A. Ustekinumab in clinical practice: response depends on dose and previous treatments. J Eur Acad Dermatol Venereol 2012; 26: 508–513.
25. van den Reek JMPA, van Lumig PPM, Driessen RJB et al. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol 2014; 170: 415–424.
26. van den Reek JMPA, Tummers M, Zweegers J et al. Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. J Eur Acad Dermatol Venereol 2015; 29: 560–565.
27. Ritchlin C, Rahman P, Kavanaugh A et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-mon and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73: 990–999.
28. Smolen JS, Kay J, Matteson EL et al. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis 2014; 73: 1811–1818.
29. Mease PJ, Fleischmann R, Deodhar AA et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73: 48–55.
30. Rudwaleit M, Van den Bosch F, Kron M et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and a history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010; 12: R117.